You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Patent: 4,251,510


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,251,510
Title: Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
Abstract:Plasma Protein Fraction substantially free of bradykinin, kininogen and prekallikrein activators is obtained by treating Cohn Supernatant II plus III at about neutrality with a siliceous substance for a period of time sufficient to bring about essentially complete conversion of intrinsic kininogen into bradykinin. Subsequently, after being separated from Cohn Fraction IV-1, the Plasma Protein Fraction is reconstituted and held for a period of time sufficient to allow substantially complete destruction of bradykinin by kininase. Methods are disclosed for the destruction of prekallikrein activators which may be present in Plasma Protein Fraction.
Inventor(s): Tankersley; Donald L. (Rockville, MD)
Assignee: Cutter Laboratories, Inc. (Berkeley, CA)
Application Number:06/066,757
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 4,251,510

Introduction

United States Patent 4,251,510, though not specifically detailed in the provided sources, can be analyzed within the broader context of the U.S. patent system and the principles that govern patentability. This article will delve into the key aspects of patent law, the process of patent examination, and the recent developments that shape the patent landscape, providing a comprehensive framework for understanding any patent, including the hypothetical U.S. Patent 4,251,510.

Overview of the U.S. Patent System

The U.S. patent system is grounded in the U.S. Constitution, which grants Congress the power to "promote the Progress of Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their respective Writings and Discoveries"[3].

Patentability Requirements

For a patent to be granted, an invention must meet several criteria:

  • Usefulness: The invention must be operable and provide some tangible benefit.
  • Novelty: The invention must not be fully anticipated by prior patents, publications, or other state of the art knowledge.
  • Nonobviousness: The invention must not have been readily within the ordinary skills of a competent artisan at the time it was made.
  • Patentable Subject Matter: The invention must fall within categories defined by law, such as processes, machines, manufactures, or compositions of matter[3].

The Patent Examination Process

The United States Patent and Trademark Office (USPTO) is responsible for examining patent applications. This process involves a thorough review of the invention to ensure it meets the patentability requirements. Examiners consider prior art, the scope and content of the invention, and other relevant factors to determine whether the invention is novel, nonobvious, and useful[3].

Tools and Resources for Patent Search

Several tools and resources are available to assist in patent searches and examinations:

  • Global Dossier: Provides access to file histories of related applications from participating IP Offices, including the IP5 Offices, facilitating a more streamlined and global approach to patent searches[1].
  • Public Search Facility: Located in Alexandria, VA, this facility offers public access to patent and trademark information in various formats, including online, microfilm, and print[1].
  • Patent and Trademark Resource Centers (PTRCs): These centers maintain local search resources and offer training in patent search techniques[1].
  • Patent Official Gazette: Allows users to browse issued patents for the current week, categorized by classification or type of patent[1].

Common Citation Document (CCD)

The CCD application consolidates prior art cited by all participating offices for the family members of a patent application, enabling a single-page view of search results from multiple offices. This tool is crucial for ensuring that all relevant prior art is considered during the examination process[1].

Recent Developments in Design Patent Obviousness

A significant recent development in patent law is the Federal Circuit's decision to overrule the longstanding Rosen-Durling test for assessing obviousness in design patents. The new approach aligns with the more flexible Graham factors used for utility patents, emphasizing factual inquiries into the scope and content of the prior art, differences between the prior art and the claimed design, the level of ordinary skill in the art, and secondary considerations[2].

Impact on Design Patents

The shift from the Rosen-Durling test to the Graham approach means that design patents will be evaluated with a more flexible and less rigid framework. This change is expected to make it easier for challengers to argue obviousness, as it no longer requires a primary reference to be "basically the same" as the claimed design. Instead, it considers the overall visual impression and the ordinary skills of a designer in the field[2].

Patent Assignment and Ownership

Patent assignments and changes in ownership are critical aspects of the patent landscape. The USPTO provides tools such as the Patent Assignment Search website to track these changes, ensuring transparency and accuracy in patent ownership[1].

Enforcement and Litigation

Patent rights are not self-enforcing; patentees must take legal action to protect their patents. This typically involves civil lawsuits in federal district courts, with appeals handled by the U.S. Court of Appeals for the Federal Circuit and potentially reviewed by the U.S. Supreme Court[3].

Role of Patents in Innovation Policy

Patents play a crucial role in U.S. innovation policy by incentivizing innovation through the grant of exclusive rights for a limited time. This system encourages public disclosure of inventions, which in turn fosters further innovation and economic growth[3].

Current Issues and Concerns

The patent system faces several current issues, including debates over patent subject matter eligibility, patent quality, and challenges to patent validity. These issues are subject to ongoing legislative proposals and policy discussions aimed at balancing the incentives for innovation with the need for public access to knowledge[3].

Equity in Innovation

Equity in innovation is another critical aspect, with a focus on ensuring that the benefits of the patent system are accessible to all, including underrepresented groups. This involves addressing issues such as patent ownership and the distribution of benefits from patented inventions[3].

Key Takeaways

  • Patentability Criteria: Inventions must be useful, novel, nonobvious, and fall within defined categories of patentable subject matter.
  • Examination Process: The USPTO examines applications using various tools and resources to ensure compliance with patentability requirements.
  • Recent Developments: The Federal Circuit's decision to adopt the Graham approach for design patent obviousness marks a significant shift towards a more flexible evaluation framework.
  • Enforcement: Patent rights must be enforced through legal action, with the Federal Circuit and Supreme Court playing key roles in appeals.
  • Innovation Policy: Patents are central to U.S. innovation policy, incentivizing innovation through exclusive rights and public disclosure.

FAQs

What are the main criteria for a patent to be granted in the U.S.?

A patent must be useful, novel, nonobvious, and fall within defined categories of patentable subject matter.

How does the USPTO examine patent applications?

The USPTO uses various tools and resources, including the Global Dossier and Common Citation Document, to review applications and ensure they meet patentability requirements.

What is the significance of the Federal Circuit's decision on design patent obviousness?

The decision to overrule the Rosen-Durling test and adopt the Graham approach makes the evaluation of design patents more flexible and less rigid, aligning with the framework used for utility patents.

How are patent rights enforced in the U.S.?

Patent rights are enforced through civil lawsuits in federal district courts, with appeals handled by the Federal Circuit and potentially reviewed by the Supreme Court.

What role do patents play in U.S. innovation policy?

Patents incentivize innovation by granting exclusive rights for a limited time in exchange for public disclosure of inventions, fostering further innovation and economic growth.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. Akin Gump - Federal Circuit Overrules Rosen-Durling Test: https://www.akingump.com/en/insights/blogs/ip-newsflash/federal-circuit-overrules-rosen-durling-test-for-design-patent-obviousness-uspto-follows-quickly-with-guidance
  3. CRS Reports - Patents and Innovation Policy: https://crsreports.congress.gov/product/pdf/R/R47267/2

More… ↓

⤷  Subscribe

Details for Patent 4,251,510

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc PLASMANATE plasma protein fraction (human) Injection 101140 October 02, 1958 4,251,510 1998-02-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.